Fig. 7

LAPTM4B expression correlates with survival probability in skin cancer metastatic patients. A, Schematic overview of the LAPTM4B transcripts. B-D, Expression of the indicated LAPTM4B transcripts in healthy and tumor samples, and their correlation with cancer overall survival. Left panels: expression of the transcript as transcripts per million (TPM) in normal skin (GTEx) and skin cancer metastatic tissues (TCGA), log¹⁰ scale. Right panels: skin cancer metastatic patient survival probability with patients grouped to either high- (>median) or low-expression groups. Bottom panels: number of patients at risk, in either stratum, at a given timepoint (unit: day). E, Stable cells expressing LAPTM4B-35-GFP, LAPTM4B-24-GFP, N-terminus-GFP, or GFP; expression in the cell lysates assessed by Western blotting. Left panel: a representative experiment. Right panel: quantification of three experiments, mean ± SEM. F, Real-time measurement of cell migration in cells stably expressing LAPTM4B-35-GFP, LAPTM4B-24-GFP, N-terminus-GFP, or GFP using the xCELLigence system. Those 6 × 10⁴ cells in serum-free medium were seeded in the top chamber; complete medium containing 10% FBS in the lower chamber served as a chemoattractant. Cell migration index measured at an interval of 15 min for 25 h. In five independent experiments, more than 15 wells for each condition were analyzed; mean ± SEM